Amneal Pharmaceuticals
AMRX
308 hedge funds and large institutions have $2.82B invested in Amneal Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 136 increasing their positions, 85 reducing their positions, and 52 closing their positions.
31,900% more call options, than puts
Call options by funds: $2.88M | Put options by funds: $9K
60% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 85
41% more capital invested
Capital invested by funds: $2B → $2.82B (+$823M)
0.75% more ownership
Funds ownership: 50.44% → 51.19% (+0.75%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
10% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 52
3% less funds holding
Funds holding: 317 → 308 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$28M |
| 2 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$11.1M |
| 3 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$10.7M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$10.2M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$13M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$11.9M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.52M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$7.88M |
| 5 |
Morgan Stanley
New York
|
-$7.22M |
AMRX Hedge Fund Activity: Q2 2026 in Review
308 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q2 2026, worth a combined $2.82B — up 41% from $2B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of AMRX and 47 opened new positions — a net loss of 5 holders — while 85 trimmed existing stakes and 136 added.
The largest buyer was BlackRock, adding an estimated $28M. The largest seller was D.E. Shaw & Co, cutting an estimated $13M.
- 308 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q2 2026, down from 317 in Q1 2026.
- Funds reported $2.82B of Amneal Pharmaceuticals stock for Q2 2026, up 41% quarter-over-quarter.
- 47 funds opened new Amneal Pharmaceuticals positions in Q2 2026 and 52 closed out, a net change of -5 holders.
- The largest Amneal Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $28M added.
- The largest Amneal Pharmaceuticals seller in Q2 2026 was D.E. Shaw & Co, an estimated $13M sold.
Based on aggregated 13F filings for Q2 2026.